Discovery of Highly Potent Inhibitors Targeting the Predominant Drug-Resistant S31N Mutant of the Influenza A Virus M2 Proton Channel
作者:Fang Li、Chunlong Ma、William F. DeGrado、Jun Wang
DOI:10.1021/acs.jmedchem.5b01910
日期:2016.2.11
With the emergence of highly pathogenic avian influenza (HPAI) H7N9 and H5N1 strains, there is a pressing need to develop direct-acting antivirals (DAAs) to combat such deadly viruses. The M2-S31N proton channel of the influenza A virus (A/M2) is one of the validated and most conserved proteins encoded by the current circulating influenza A viruses; thus, it represents a high-profile drug target for
Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases associated with the proteasome. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. Oral administration of these peptide-based proteasome inhibitors is possible due to their bioavailability profiles.
肽基化合物包括含杂原子的三元环,能有效并选择性地抑制与蛋白酶体相关的 N-末端亲核(Ntn)水解酶的特定活性。肽基化合物包括环氧化物或氮丙啶,并在 N 端进行了官能化。除其他治疗作用外,肽基化合物还具有抗炎和抑制细胞增殖的作用。由于这些肽基蛋白酶体抑制剂具有生物利用度高的特点,因此可以口服给药。
MALONONITRILE COMPOUND AS PESTICIDES
申请人:Sumitomo Chemical Company, Limited
公开号:EP1704143B1
公开(公告)日:2008-09-03
Compounds for Enzyme Inhibition
申请人:Zhou Han-Jie
公开号:US20090203698A1
公开(公告)日:2009-08-13
Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases associated with the proteasome. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. Oral administration of these peptide-based proteasome inhibitors is possible due to their bioavailability profiles.